Remission induction therapy is a treatment method aimed at achieving remission by reducing leukemia cells below a certain threshold. This treatment may include chemotherapy and/or targeted therapies. If no additional complications arise, the process of eliminating leukemia cells from the bone marrow and replacing them with normal cells can take approximately one month.
Various chemotherapy protocols are available for remission induction therapy. The success rates of these protocols are generally similar. Commonly used chemotherapy agents include doxorubicin, vincristine, and asparaginase. Depending on the subtype of Acute Lymphoblastic Leukemia (ALL), targeted drugs like Rituximab may also be added to the treatment. The hematology team will determine the most suitable protocol based on the patient's individual characteristics and the center's experience.